MicroRNA-384 inhibits proliferation migration and invasion of glioma by targeting at CDC42
Authors Gu G, Wang L, Zhang J, Wang H, Tan T, Zhang G
Received 27 February 2018
Accepted for publication 18 April 2018
Published 16 July 2018 Volume 2018:11 Pages 4075—4085
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr XuYu Yang
Gengshi Gu,1,* Li Wang,1,* Junchen Zhang,1 Hao Wang,2 Tan Tan,1 Guangning Zhang1
1Department of Neurosurgery, Affiliated Hospital of Jining Medical University, Jining, Shandong 272000, People’s Republic of China; 2Department of Clinical Laboratory, Chinese People’s Liberation Army General Hospital, Beijing, 100700, People’s Republic of China
*These authors contributed equally to this work
Background: Accumulative evidence indicated that microRNAs (miRNAs) play a critical role in carcinogenesis and biological behaviors of glioma. Further bio-molecular mechanisms of miRNAs in glioma cells remain largely unknown, which can contribute to novel therapeutic strategy.
Methods: In the present study, we detected the expression level of miR-384 by RT-PCR and Western blot. Meanwhile, Gain and loss function assay of miR-384 by transfection of miR-384 mimics and inhibitor. Moreover, wild and mutant psiCHECK-2-CDC42-3’-UTR luciferase reporter vectors were constructed and transfected into glioma cells with miR-384 mimics or miR-NC.
Results: miR-384 was dramatically down-regulated in human glioma tissues. It was also demonstrated that miR-384 significantly inhibited proliferation, migration and invasion of glioma cells. Cell division cycle 42 (Cdc42) was a direct target of miR-384 according to results of RT-PCR and Western blotting.
Conclusion: Our research demonstrated that miR-384 exerted an inhibitory effect on proliferation, migration and invasion of glioma via suppressing the expression of CDC42, meaning that miR-384 may be regarded as a potential target in the treatment of glioma.
Keywords: miR-384, CDC42, glioma, proliferation, invasion
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]